Brest Cancer Screening and Mobile Web App Intervention: Perceptions, Knowledge, and Needs among Native Women

Abstract American Indian (AI) women have the highest breast cancer mortality and lowest breast cancer screening rates in the U.S. The present study, in collaboration with the Yankton Sioux Tribe (YST) in South Dakota, sought to (1) identify the general public/professionals’ knowledge, attitudes, and needs for a mobile web app for breast cancer screening (wMammogram) intervention, and (2) inform development of the wMammogram intervention to improve Breast Cancer screening among YST women. Following a community-based participatory research approach, two focus groups were conducted in October 2020 with a total of 22 YST women aged 40-70 years, including 17 elderly women. Each group consisted of 11 community leaders, members, healthcare professionals. Qualitative analysis was conducted using grounded theory. Participants in both groups were generally favorable toward the wMammogram intervention, and noted a potential health benefit, particularly for women in their 50s to 60s. Key areas identified by participants for intervention include: (1) needs for better knowledge of breast cancer, screening, and prevention/early detection, (2) culturally tailored educational materials rooted in AI cultural values and beliefs (e.g., holistic wellness approach, Native lifestyles), (3) barriers (e.g., fear), (4) motivators (e.g., reminders), and (5) suggestions for acceptability (e.g., content and structure of messages). These results suggest that the wMammogram intervention, which is culturally tailored and addresses the community’s concerns, can be a feasible, acceptable, and effective tool to promote breast cancer screening among YST women. The results informed the development of an innovative health intervention to help reduce health disparities experienced in Indian Country.

Download Full-text

Worldwide Review and Meta-Analysis of Cohort Studies Measuring the Effect of Mammography Screening Programmes on Incidence-Based Breast Cancer Mortality

Cancers ◽

10.3390/cancers12040976 ◽

2020 ◽

Vol 12 (4) ◽

pp. 976

Author(s):

Amanda Dibden ◽

Judith Offman ◽

Stephen W. Duffy ◽

Rhian Gabe

Keyword(s):

Breast Cancer ◽

Cancer Screening ◽

Breast Cancer Screening ◽

Cancer Mortality ◽

Mammography Screening ◽

Meta Analysis ◽

Breast Cancer Mortality ◽

Substantial Reduction ◽

Healthcare Setting ◽

Actual Attendance

In 2012, the Euroscreen project published a review of incidence-based mortality evaluations of breast cancer screening programmes. In this paper, we update this review to October 2019 and expand its scope from Europe to worldwide. We carried out a systematic review of incidence-based mortality studies of breast cancer screening programmes, and a meta-analysis of the estimated effects of both invitation to screening and attendance at screening, with adjustment for self-selection bias, on incidence-based mortality from breast cancer. We found 27 valid studies. The results of the meta-analysis showed a significant 22% reduction in breast cancer mortality with invitation to screening, with a relative risk of 0.78 (95% CI 0.75–0.82), and a significant 33% reduction with actual attendance at screening (RR 0.67, 95% CI 0.61–0.75). Breast cancer screening in the routine healthcare setting continues to confer a substantial reduction in mortality from breast cancer.

Download Full-text

Corrigendum: Breast cancer mortality after implementation of organized population-based breast cancer screening in Norway

JNCI Journal of the National Cancer Institute ◽

10.1093/jnci/djaa045 ◽

2020 ◽

Vol 112 (10) ◽

pp. 1072-1074

Keyword(s):

Breast Cancer ◽

Cancer Screening ◽

Breast Cancer Screening ◽

Cancer Mortality ◽

Breast Cancer Mortality ◽

Population Based

Download Full-text

Advanced Breast Cancer and Breast Cancer Mortality in Randomized Controlled Trials on Mammography Screening

Journal of Clinical Oncology ◽

10.1200/jco.2009.22.7041 ◽

2009 ◽

Vol 27 (35) ◽

pp. 5919-5923 ◽

Cited By ~ 63

Author(s):

Philippe Autier ◽

Clarisse Héry ◽

Jari Haukka ◽

Mathieu Boniol ◽

Graham Byrnes

Keyword(s):

Breast Cancer ◽

Cancer Screening ◽

Advanced Breast Cancer ◽

Breast Cancer Screening ◽

Advanced Cancer ◽

Cancer Mortality ◽

Breast Cancer Mortality ◽

Advanced Breast ◽

Published Data ◽

National Breast

Purpose We assessed changes in advanced cancer incidence and cancer mortality in eight randomized trials of breast cancer screening. Patients and Methods Depending on published data, advanced cancer was defined as cancer ≥ 20 mm in size (four trials), stage II+ (four trials), and ≥ one positive lymph node (one trial). For each trial, we obtained the estimated relative risk (RR) and 95% CI between the intervention and control groups, for both breast cancer mortality and diagnosis of advanced breast cancer. Using a meta-regression approach, log(RR-mortality) was regressed on log(RR-advanced cancer), weighting each trial by the reciprocal of the square of the standard error of log(RR) for mortality. Results RR for advanced breast cancer ranged from 0.69 (95% CI, 0.61 to 0.78) in the Swedish Two-County Trial to 0.97 (95% CI, 0.97 to 1.25) in the Canadian National Breast Screening Study-1 (NBSS-1) trial. Log(RR)s for advanced cancer were highly predictive of log(RR)s for mortality (R2 = 0.95; P < .0001), and the linear regression curve had a slope of 1.00 (95% CI, 0.76 to 1.25) after fixing the intercept to zero. The slope changed only slightly after excluding the Two-County Trial and the Canadian NBSS-1 and NBSS-2 trials. Conclusion In trials on breast cancer screening, for each unit decrease in incidence of advanced breast cancer, there was an equal decrease in breast cancer mortality. Monitoring of incidence of advanced breast cancer may provide information on the current impact of screening on breast cancer mortality in the general population.

Download Full-text

More Than Just a Mammogram: Breast Cancer Screening Perspectives of Relatives of Women With Intellectual Disability

Intellectual and Developmental Disabilities ◽

10.1352/1934-9556-52.6.444 ◽

2014 ◽

Vol 52 (6) ◽

pp. 444-455 ◽

Cited By ~ 8

Author(s):

Nechama W. Greenwood ◽

Deborah Dreyfus ◽

Joanne Wilkinson

Keyword(s):

Breast Cancer ◽

Quality Of Life ◽

Health Care ◽

Intellectual Disability ◽

Cancer Screening ◽

Breast Cancer Screening ◽

Breast Cancer Mortality ◽

Family Members ◽

Well Being

Abstract Women with intellectual disability (ID) have similar rates of breast cancer as the general public, but higher breast cancer mortality and lower rates of regular screening mammography. Screening rates are lowest among women who live with their families. Though women with ID often make decisions in partnership with their relatives, we lack research related to family member perspectives on mammography. We conducted a qualitative study of family members of women with ID, with an interview guide focused on health care decision making and experiences, and breast cancer screening barriers, facilitators, and beliefs as related to their loved ones. Sixteen family members underwent semistructured interviews. Important themes included mammography as a reference point for other social and cultural concerns, such as their loved one's sexuality or what it means to be an adult woman; fear of having to make hard decisions were cancer to be diagnosed acting as a barrier to screening; a focus on quality of life; and desire for quality health care for their loved one, though quality care did not always equate to regular cancer screening. Adults with ID are valued members of their families, and their relatives are invested in their well-being. However, families fear the potentially complicated decisions associated with a cancer diagnosis and may choose to forgo screening due to misinformation and a focus on quality of life. Effective interventions to address disparities in mammography should focus on adults with ID and their families together, and incorporate the family context.

Download Full-text

Breast cancer screening programmes in selected European countries and Poland

Journal of Education, Health and Sport ◽

10.12775/34598 ◽

2021 ◽

Vol 11 (7) ◽

pp. 11-21

Author(s):

Adam Jasiura ◽

Izabela Dera ◽

Karolina Szlachcic ◽

Mateusz Gorzel ◽

Joanna Zmonarska

Keyword(s):

Breast Cancer ◽

Cancer Screening ◽

Mortality Rate ◽

Breast Cancer Screening ◽

Malignant Tumors ◽

Breast Cancer Mortality ◽

Breast Cancer Incidence ◽

Screening Tests ◽

The European Union ◽

Screening Programs

Breast neoplasms are the most common malignant tumors among women. In recent years breast cancer incidence rate has increased. Due to this fact the European Union presents evidence-based guidelines on breast cancer screening and diagnosis. Recommended and commonly used screening test is mammography. The effectiveness of prophylaxis is measured by a decrease in breast cancer mortality rate. Detailed recommendations in EU member countries differ from those presented by the EU institutions. This paper compares the screening programme in Poland to screening programmes in other EU members. The evaluation considers compliance with European screening guidelines and changes in mortality rates since the introduction of the screening programs. General guidelines in Poland are close to European ones. However, some Polish health centers still use analog mammography instead of recommended digital mammography. Furthermore, mortality rate changes in Poland maintain on a constant level due to women’s reluctant participation in screening tests.

Download Full-text

Breast cancer screening for carriers of ATM, CHEK2, and PALB2 pathogenic variants: A comparative modeling analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.10500 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. 10500-10500

Author(s):

Kathryn P. Lowry ◽

H. Amarens Geuzinge ◽

Natasha K. Stout ◽

Oguzhan Alagoz ◽

John M. Hampton ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Screening ◽

Breast Cancer Screening ◽

Cancer Mortality ◽

Breast Cancer Mortality ◽

Breast Cancer Incidence ◽

Simulation Models ◽

Pathogenic Variants ◽

Life Years ◽

Incidence And Mortality

10500 Background: Inherited pathogenic variants in ATM, CHEK2, and PALB2 confer moderate to high risks of breast cancer. The optimal approach to screening in these women has not been established. Methods: We used two simulation models from the Cancer Intervention and Surveillance Modeling Network (CISNET) and data from the Cancer Risk Estimates Related to Susceptibility consortium (CARRIERS) to project lifetime breast cancer incidence and mortality in ATM, CHEK2, and PALB2 carriers. We simulated screening with annual mammography from ages 40-74 alone and with annual magnetic resonance imaging (MRI) starting at ages 40, 35, 30, and 25. Joint and separate mammography and MRI screening performance was based on published literature. Lifetime outcomes per 1,000 women were reported as means and ranges across both models. Results: Estimated risk of breast cancer by age 80 was 22% (21-23%) for ATM, 28% (26-30%) for CHEK2, and 40% (38-42%) for PALB2. Screening with MRI and mammography reduced breast cancer mortality by 52-60% across variants (Table). Compared to no screening, starting MRI at age 30 increased life years (LY)/1000 women by 501 (478-523) in ATM, 620 (587-652) in CHEK2, and 1,025 (998-1,051) in PALB2. Starting MRI at age 25 versus 30 gained 9-12 LY/1000 women with 517-518 additional false positive screens and 197-198 benign biopsies. Conclusions: For women with ATM, CHEK2, and PALB2 pathogenic variants, breast cancer screening with MRI and mammography halves breast cancer mortality. These mortality benefits are similar to those for MRI screening for BRCA1/2 mutation carriers and should inform practice guidelines.[Table: see text]

Download Full-text

Breast cancer screening literacy information on online platforms: A content analysis of YouTube videos

Breast Disease ◽

10.3233/bd-201028 ◽

2021 ◽

pp. 1-7

Author(s):

Jasleen Brar ◽

Ayisha Khalid ◽

Mahzabin Ferdous ◽

Tasnima Abedin ◽

Tanvir C. Turin

Keyword(s):

Breast Cancer ◽

Cancer Screening ◽

Breast Cancer Screening ◽

Breast Cancer Mortality ◽

Final Analysis ◽

Screening Methods ◽

Wide Audience ◽

Healthcare Resources ◽

Screening Guidelines ◽

Preventative Measures

BACKGROUND: The YouTube platform has great potential of serving as a healthcare resource due to its easy accessibility, navigability and wide audience reach. Breast cancer screening is an important preventative measure that can reduce breast cancer mortality by 40%. Therefore, platforms being used as a healthcare resources, such as YouTube, can and should be used to advocate for essential preventative measures such as breast cancer screening. METHODS: In this study, the usefulness of videos related to breast cancer and breast cancer screening were analyzed. Videos were first screened for inclusion and then were categorized into very useful, moderately useful, somewhat useful, and not useful categories according to a 10-point criteria scale developed by medical professionals based on existing breast cancer screening guidelines. Two reviewers independently assessed each video using the scale. RESULTS: 200 videos were identified in the preliminary analysis (100 for the search phrase ‘breast cancer’ and 100 for the search phrase ‘breast cancer screening’). After exclusion of duplicates and non-relevant videos, 162 videos were included in the final analysis. We found the following distribution of videos: 4.3% very useful, 17.9% moderately useful, 39.5% somewhat useful, and 38.3% not useful videos. There was a significant association between each of the following and the video’s level of usefulness: video length, the number of likes, and the uploading source. Longer videos were very useful, somewhat useful videos were the most liked, personally produced videos were the most not useful, and advertisements produced the highest ratio of very useful to not useful videos. CONCLUSION: It is necessary to create more reliable and useful healthcare resources for the general population as well as to monitor health information on easily accessible social platforms such as YouTube.

Download Full-text

Breast cancer screening in average-risk women: towards personalized screening

British Journal of Radiology ◽

10.1259/bjr.20190660 ◽

2019 ◽

Vol 92 (1103) ◽

pp. 20190660 ◽

Cited By ~ 1

Author(s):

Almir GV Bitencourt ◽

Carolina Rossi Saccarelli ◽

Christiane Kuhl ◽

Elizabeth A Morris

Keyword(s):

Breast Cancer ◽

Cancer Screening ◽

Breast Cancer Screening ◽

Task Force ◽

Early Stage ◽

Breast Cancer Mortality ◽

Mammographic Screening ◽

Screening Strategy ◽

Average Risk ◽

Early Stage Disease

Breast cancer screening is widely recognized for reducing breast cancer mortality. The objective in screening is to diagnose asymptomatic early stage disease, thereby improving treatment efficacy. Screening recommendations have been widely debated over the past years and controversies remain regarding the optimal screening frequency, age to start screening, and age to end screening. While there are no new trials, follow-up information of randomized controlled trials has become available. The American College of Physicians recently issued a new guidance statement on screening for breast cancer in average-risk women, with similar recommendations to the U.S. Preventive Services Task Force and to European guidelines. However, these guidelines differ from those ofother American specialty societies. The variations reflect differences in the organizations’ values, the metrics used to evaluate screening results, and the differences in healthcare organization (individualized or state-organized healthcare). False-positive rates and overdiagnosis of biologically insignificant cancer are perceived as the most important potential harms associated with mammographic screening; however, there is limited evidence on their actual consequences. Most specialty societies agree that physicians should offer mammographic screening at age 40 years for average-risk women and discuss its benefits and potential harms to achieve a personalized screening strategy through a shared decision-making process.

Download Full-text